Wells Fargo & Company Virpax Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.24 - $0.82 $0 - $3	4 Added 6.35%	67 $0
Q3 2023 Nov 13, 2023	BUY	$0.76 - $1.1 $0 - $1	1 Added 1.61%	63 $0
Q2 2023 Aug 15, 2023	BUY	$0.64 - $1.09 $1 - $2	2 Added 3.33%	62 $0
Q1 2023 May 12, 2023	BUY	$0.67 - $1.15 $0 - $1	1 Added 1.69%	60 $0
Q4 2022 Feb 13, 2023	BUY	$0.62 - $12.0 $0 - $12	1 Added 1.72%	59 $0
Q3 2022 Nov 14, 2022	BUY	$1.15 - $11.9 $1 - $11	1 Added 1.75%	58 $0
Q2 2022 Aug 12, 2022	BUY	$1.22 - $2.25 $4 - $9	4 Added 7.55%	57 $0
Q1 2022 May 16, 2022	BUY	$1.86 - $3.61 $1 - $3	1 Added 1.92%	53 $0
Q4 2021 Feb 14, 2022	SELL	$3.19 - $4.89 $1,595 - $2,445	-500 Reduced 90.58%	52 $0
Q3 2021 Nov 15, 2021	BUY	$4.14 - $22.9 $2,239 - $12,388	541 Added 4918.18%	552 $3,000
Q2 2021 Aug 16, 2021	BUY	$3.84 - $6.0 $42 - $66	11 New	11 $0

Ticker VRPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,714,600
Market Cap $7.15M
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical no...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.